Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour

Andrew J. Wagner, Mark Agulnik, Michael C. Heinrich, Daruka Mahadevan, Richard F. Riedel, Margaret Von Mehren, Jonathan Trent, George D. Demetri, Christopher L. Corless, Murray Yule, John F. Lyons, Aram Oganesian, Harold Keer

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Fingerprint Dive into the research topics of 'Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour'. Together they form a unique fingerprint.

Medicine & Life Sciences